
Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD
BioCentury
|
July 17, 2023
X min read
BioCentury
|
July 17, 2023
Share on Social
More like this
Media
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Press
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Media
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now
Press
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now